Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

Next Previous
Search
Trial Profile

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 31 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CM 24 (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan
  • Indications Adenocarcinoma; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors FameWave

    • Most Recent Events

    • 27 Dec 2024 Status changed from active, no longer recruiting to completed.
    • 06 Oct 2024 According to a Purple Biotech media release, survival, exploratory biomarkers and effect on Neutrophil Extracellular Traps from this trial were presented at the American Association for Cancer Research (AACR) Special Conference: Pancreatic Cancer in Boston in a scientific poster.
    • 25 Sep 2024 According to a Purple Biotech media release, topline data from this trial are expected in the fourth quarter of 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top